New York, NY -- (SBWIRE) -- 01/22/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Two Harbors Investment Corp (NYSE:TWO), Orexigen Therapeutics, Inc (NASDAQ:OREX), Real Goods Solar, Inc (NASDAQ:RSOL), CEL-SCI Corporation (NYSEMKT:CVM)
Two Harbors Investment Corp (NYSE:TWO) showed a volume of 3.08 million shares by the end of last trade whereas the average volume of the stock remained 4.20million shares. The stock opened the session at $9.81 but then moved to $9.86. At that price, the stock showed a positive performance of 0.51%. Two Harbors Investment Corp. (Two Harbors) operates as a real estate investment trust (REIT). The Company is focused on investing in, financing and managing residential mortgage-backed securities (RMBS), residential mortgage loans, residential real properties, and other financial assets.
Will TWO Continue To Move Higher? Find Out Here
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $7.00 and closed the session at $6.87. The stock showed a positive performance of 0.88% in previous trading session. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety,
For How Long OREX will fight for Profitability? Read This Trend Analysis report
Real Goods Solar, Inc (NASDAQ:RSOL) opened the session at $4.52 and closed the session at $4.53. The stock showed a positive performance of 2.26% in previous trading session. The beta of the stock remained 1.37. Real Goods Solar, Inc. is a solar energy company serving the commercial, residential and utility customers. As of February 5, 2013, the Company had installed more than 14,500 solar power systems representing over 100 megawatts of 100% clean renewable energy.
Why Should Investors Buy RSOL After The Recent Gain? Just Go Here and Find Out
CEL-SCI Corporation (NYSEMKT:CVM) the stock advanced 9.83% and finished the session at $0.950. Traded with volume of 2.90 million shares in the prior session and the average volume of the stock remained 1.47 million shares. The beta of the stock remained 2.12. CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology,
Will CVM Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)